What is the recommended steroid treatment for severe alcoholic hepatitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Steroid Treatment for Severe Alcoholic Hepatitis

Prednisolone 40 mg daily for 28 days is the recommended first-line treatment for severe alcoholic hepatitis, defined as having a Maddrey Discriminant Function (mDF) score ≥32 or hepatic encephalopathy. 1

Diagnosis and Assessment

  • Severe alcoholic hepatitis requiring steroid treatment is defined by:

    • mDF score ≥32 1
    • MELD score >21 1
    • Glasgow Alcoholic Hepatitis Score (GAHS) ≥9 1
    • Presence of hepatic encephalopathy 1
  • Patients with mild alcoholic hepatitis (mDF <32, MELD <18, GAHS <8) generally improve with abstinence and supportive care alone 1

First-Line Treatment

  • Prednisolone 40 mg daily for 28 days is the standard treatment regimen for severe alcoholic hepatitis 1

  • Methylprednisolone 32 mg daily is an acceptable alternative to prednisolone 1, 2

  • Steroid therapy has been shown to improve short-term (28-day) survival in patients with severe alcoholic hepatitis 1, 2

Contraindications to Steroid Therapy

  • Steroids are contraindicated in patients with: 1
    • Active infection or sepsis
    • Gastrointestinal bleeding
    • Acute renal failure
    • Acute pancreatitis

Monitoring Response to Treatment

  • Early response to steroid treatment should be assessed at day 7 using: 1

    • Early Change in Bilirubin Level (ECBL): Bilirubin level at day 7 should be lower than day 1
    • Lille model score: Categorizes patients as:
      • Complete responders (score ≤0.16)
      • Partial responders (score 0.16-0.56)
      • Null responders (score ≥0.56)
  • 28-day survival rates based on Lille score: 1

    • Complete responders: 91.1%
    • Partial responders: 79.4%
    • Null responders: 53.3%

Treatment Algorithm

  1. For patients with mDF ≥32 without contraindications:

    • Start prednisolone 40 mg daily for 28 days 1
    • Assess response at day 7 using Lille model 1
  2. If Lille score <0.56 (responder):

    • Continue prednisolone for full 28-day course 1
    • Consider tapering over 2 weeks after completion 1, 3
  3. If Lille score ≥0.56 (null responder):

    • Discontinue steroids 1
    • Consider liver transplantation evaluation in appropriate candidates 1
  4. For patients with contraindications to steroids:

    • Pentoxifylline 400 mg three times daily for 28 days can be considered as an alternative 1
    • However, recent evidence shows pentoxifylline is less effective than prednisolone 1, 4

Alternative Treatments

  • Pentoxifylline:

    • Less effective than prednisolone but may be used when steroids are contraindicated 1
    • Primarily reduces mortality by decreasing hepatorenal syndrome 1
    • Recent guidelines state it "must no longer be offered to patients with severe alcoholic hepatitis because of its ineffectiveness" 1
  • Combination therapy:

    • Combining prednisolone and pentoxifylline shows no survival benefit over prednisolone alone 1, 5, 6
  • N-acetylcysteine with corticosteroids:

    • May improve short-term survival at 1 and 3 months 1
    • Not consistently recommended as confirmatory studies are needed 1

Common Pitfalls and Caveats

  • Steroid therapy should not be delayed excessively; however, a systematic evaluation taking up to a week before initiation is reasonable to rule out contraindications 3

  • Infections are a common complication of steroid therapy, occurring in 13% of treated patients versus 7% in untreated patients 4, 3

  • Long-term outcomes depend primarily on achieving alcohol abstinence, which should be strongly recommended to all patients 1

  • The 6-month survival rate is 82% in patients with confirmed ECBL but only 23% in those without ECBL 1

  • Despite improving short-term survival, steroids have not consistently shown benefits in medium or long-term survival 1, 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.